Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.43 |
| ▸ | TNF | P01375 | 13/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598585 | 0.80 | TNF (0.48) | CYSLTR2CYSLTR1TNFGAALMNA | |
| SCHEMBL597363 | 0.70 | TSHR (0.57) | CYSLTR2CYSLTR1TNFGAA | |
| SCHEMBL19900035 | 0.70 | CYP4Z1 (0.48) | TNFGAAFAAH | |
| SCHEMBL28288493 | 0.68 | CYP4F2 (0.51) | GAA | |
| SCHEMBL13249212 | 0.68 | FAAH (0.46) | TNFGAAFAAH | |
| SCHEMBL13755359 | 0.67 | CYP4F2 (0.47) | TNFLMNA | |
| SCHEMBL3748048 | 0.66 | HSD17B10 (0.47) | TNFGAA | |
| SCHEMBL6686500 | 0.66 | CYP4F2 (0.49) | LMNA | |
| SCHEMBL4162786 | 0.65 | MAPK1 (0.42) | GAALMNA | |
| SCHEMBL597651 | 0.65 | MCL1 (0.54) | TNFGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206698-B1 | Ethynylindole compounds | ONO PHARMACEUTICAL CO (JP) | 2012-07-18 | — | — | EP | disclosed |
| US-8115014-B2 | Ethynylindole compounds | ONO Pharmaceuticals, Co., Ltd. (JP) | 2012-02-14 | — | — | US | disclosed |
| EP-2206698-A1 | Ethynylindole compounds | ONO Pharmaceutical Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20100160647-A1 | ETHYNYLINDOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160647-A1 | ETHYNYLINDOLE COMPOUNDS | CYSLTR2, CYSLTR1, LTB4R2 | CYSLTR2 1/4885CYSLTR1 2/4885TNF 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.